| Net income | |
| Stock compensation expense | 592K |
| Provision for doubtful accounts and sales returns | |
| Depreciation and amortization | 939K |
| Deferred income taxes | |
| Net increase (decrease) in billings in excess of costs | 268K |
| Accounts receivable | -1.76M |
| Inventories | -1.09M |
| Prepaid income taxes | |
| Prepaid expenses and other current assets | -92K |
| Accounts payable and accrued expenses | |
| Income taxes payable | |
| Net cash provided by operating activities | |
| Purchases of property, plant and equipment | -1.34M |
| Acquisition of Biomedical technologies | |
| Decrease in other assets | |
| Net cash used in investing activities | |
| Issuance of common stock | 11K |
| Repayment of long term debt | -740K |
| Preferred stock dividends paid | |
| Net cash used in financing activities | |
| Effect of exchange rates on cash and cash equivalents | -81K |
| Net increase in cash and cash equivalents | -1.06M |
| Cash and cash equivalents, beginning | 1.3M |
| Cash and cash equivalents, ending | 232K |